Celltrion Healthcare and 180 Life Sciences Enter Into Memorandum of Understanding for a Supply Agreement for the Ongoing Supply of Drug for Anti-TNF Product Trials for Novel Indications
Yahoo! Finance
Three Anti-TNF Product Candidates To Be Included in Expected Global AgreementPALO ALTO, Calif., Sept. 20, 2021 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, today announced that they have entered into a Memorandum of Understanding, (“MOU”) with Celltrion Healthcare, a leading biopharmaceutical c
Continue Reading